Abstract
Awhole-genome approach was used to investigate the genetic determinants of cytarabineinduced cytotoxicity. We performed a meta-analysis of genome-wide association studies involving 523 lymphoblastoid cell lines (LCLs) from individuals of European, African, Asian, and African American ancestry. Several of the highest-ranked single-nucleotide polymorphisms (SNPs) were within the mutated in colorectal cancers (MCC) gene. MCC expression was induced by cytarabine treatment from1.7- to 26.6-fold in LCLs.A total of 33 SNPs ranked at the top of the meta-analysis (P < 10-5) were successfully tested in a clinical trial of patients randomized to receive low-dose or high-dose cytarabine plus daunorubicin and etoposide; of these, 18 showed association (P < .05) with either cytarabine 50% inhibitory concentration in leukemia cells or clinical response parameters (minimal residual disease, overall survival (OS), and treatment-relatedmortality). This count (n518) was significantly greater than expected by chance (P5 .016). For rs1203633, LCLs with AA genotype weremore sensitive to cytarabine-induced cytotoxicity (P 5 1.313106) andAA (vs GA or GG) genotype was associated with poorer OS (P 5 .015), likely as a result of greater treatment-related mortality (P 5 .0037) in patients with acute myeloid leukemia (AML). This multicenter AML02 study trial was registered at www.clinicaltrials.gov as #NCT00136084.
Original language | English (US) |
---|---|
Pages (from-to) | 4366-4376 |
Number of pages | 11 |
Journal | Blood |
Volume | 121 |
Issue number | 21 |
DOIs | |
State | Published - May 23 2013 |
Bibliographical note
Funding Information:This work was supported by grants from: the Leukemia and Lymphoma Society, Specialized Center of Research grant (M.E.D.); the National Institutes of Health, National Institute of General Medical Sciences grant U01 GM61393 (M.E.D., N.J.C.); the National Human Genome Research Institute R21HG006367 (W.Z., M.E.D.); Clinical Therapeutics, Training grant 5T32GM007019 (C.M.H.); the Department of Defense, Breast Cancer Research Program grant BC087674 (M.W.); the National Institutes of Health, National Cancer Institute, Cancer Biology Training grants T32CA009594 (H.E.W.) and R01CA132946 (J.K.L.); and the Cancer Research Foundation of the University of Chicago Comprehensive Cancer Center (M.E.D.).
Publisher Copyright:
© 2013 by The American Society of Hematology.